Tacalyx is a biotech company focused on developing anti-TACA therapies that specifically target tumor-associated carbohydrate antigens in cancer cells. This approach aims to improve the specificity and efficacy of cancer treatments, providing more effective therapeutic options for oncology patients.
Funding
$23.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers express Tumor-Associated Carbohydrate Antigens (TACAs) at high levels, but these antigens are largely absent from healthy adult tissues. This differential expression is not effectively exploited by current cancer therapies, which often lack specificity and can cause significant off-target toxicity.
Solution
Tacalyx is developing a pipeline of first-in-class immunotherapeutics that target TACAs to selectively destroy cancer cells while sparing healthy tissue. Their approach leverages the unique expression patterns of TACAs on tumors to deliver therapeutic agents directly to the cancer cell. By targeting these cancer-specific sugars, Tacalyx aims to improve the efficacy and safety profiles of cancer treatments across multiple solid tumors. Their assets are amenable to various treatment modalities, including antibody-drug conjugates and T cell engagers.
Target Audience
The primary target audience includes oncology patients with solid tumors expressing TACAs, as well as clinicians seeking more effective and targeted cancer therapies.
Features
- Pipeline of first-in-class assets targeting different TACAs
- Modalities include antibody-drug conjugates and T cell engagers
- Focus on solid human cancers
- Exploits unique sugar patterns found on cancer cells
- Development of ultra-small antibodies (nanobodies) that bind to TACAs